View Older Stories View More Recent Stories
-
Midday movers: Southwest Airlines, CrowdStrike, KKR rise; AMD falls
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
-
Morgan Stanley Reiterates Equalweight Rating on Moderna (MRNA)
-
Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'
-
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
-
Moderna (MRNA) Reports Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

